Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT-COPD
ISRCTN14321370Phase 2Active, not recruiting
- Sponsor
- University of Leicester
- Start
- May 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of metformin and galantamine in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University of Leicester. Primary endpoints: Adverse events of CTCAE grade 3 or higher at least possibly related to investigational product, Serious adverse events at least possibly related to investigational product and 2 more. Started May 2025; status: active, not recruiting.
02
Drugs
metformingalantamine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN14321370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14321370.